# Merck licenses a KRAS G12D inhibitor for $400M upfront

> **Newsylist Open Intelligence Dossier** · First detected: 2026-09-28 22:30 UTC · Category: Business · Sources: 5 · Current Velocity: 3.35

## Intelligence Brief
"Merck licenses a KRAS G12D inhibitor for $400M upfront" developed substantial multi-source reporting across the Business sector, tracked across 5 distinct newsrooms by Newsylist.


Key reporting was led by Reuters, BioSpace, Business Wire and Fierce Biotech. Coverage velocity and cross-outlet momentum were measured using Newsylist open coverage telemetry.


Synthesized from multi-source international reporting and live coverage telemetry under Newsylist open intelligence methodology.

## Verified Facts & Key Claims
### What drove coverage for Merck licenses a KRAS G12D inhibitor for $400M upfront?
Coverage spiked when 5 independent newsrooms published 6 verified reports during this coverage cycle.

### How did Newsylist track this trend?
Newsylist monitored article arrival rates, source diversity, and cross-outlet validation in real time.

## Key People, Organizations & Locations
Merck, KRAS, G12D

## Multi-Source Evidence Table
| Source Outlet | Headline | Published (UTC) | Verification URL |
|---|---|---|---|
| Reuters | US drugmakers turn to China for licensing deals | 2026-09-28 14:00 | [Source Link](https://news.google.com/rss/articles/CBMimAFBVV95cUxQWkJGbFUwTzg3ZWQ5OUxVcjR0MzN0NXhSRmk3Ukh4RFFkRkF3bFFKOGMtQzZ5WGVYNUlNSmE1Y0pKa01mSHp4ZWdqT0Q0Nkh1ZGl3cHZuZlNVang0aHEyeENsVGdfdDhOSmY5aE1DNlVPdWloQm5Gb182WmZrallZYjI5NDdQbVNENmQwVnZGWmhMMjJZQ09xWQ?oc=5) |
| BioSpace | Merck inks up to $2.13B deal to dine with SciBrunch, gain rights to preclinical KRAS inhibitor | 2026-09-28 14:00 | [Source Link](https://news.google.com/rss/articles/CBMiwAFBVV95cUxQU2dkNG5aektCUnhDSWdWV21kQnFZQTlVWkF5cjlVa3RnVE9aU1dRZXF1dE1XZVJWcWx2VUZIcXptR2Fmd20xbGVaSTNSU2NNS0NMc1p1bEttREVtdktCNk1zVUZJcXNERnFLeTRBUkQ4dWhQREdmY05OUFd5STdIWVhjY2JKcjg5YUhKLUk1VTI2cVdMcXNJUE9LeVZHMTBKR2FfamI2akJ4LTFkUUEwTXB6S2k5RXJVak15SG9Uc2M?oc=5) |
| Business Wire | Merck Enters into Exclusive Global License Agreement with SciBrunch Therapeutics for SPR2015, an Investigational Oral KRAS G12D (ON) Inhibitor | 2026-09-28 14:00 | [Source Link](https://news.google.com/rss/articles/CBMiogJBVV95cUxNTF93RVBSRGNnVEt3QVlNTFVwUlh6NzJzZkJTWUcwTW1FNE91cW5JVVNaREpDNURPTXhKSjgyeEg3ZW9iYnBzWUUtQU1yWmRPSnphRHJnOTJ6ZWdRSms5T05jaTBySzFsS0wzeHp3YUw2M21xQTB5M0hfcEZDT1pVSWF1Zk9mTW1PQUl1S042djUyclltTThjdjVsYm9IR1VaMUF5SGc5b1lWcVU2cDFuQ2ZaQ1o0M3lFRVB1UUY2Y1hWVHpuUlM2S2l6NHRYQkdtSjM1eTUxUVZfY1VUTlNyVDRWajJVMjU0ZUc0WW9YemliSTlyX3dVOGppbk5FYUNWRUdpYjFwNzU3NVdiSFJTb3FyRFVyVzBZb2dRdTY3WU5UZw?oc=5) |
| Fierce Biotech | Merck pens $2.1B deal with China’s SciBrunch to chase KRAS G12D | 2026-09-28 14:00 | [Source Link](https://news.google.com/rss/articles/CBMilAFBVV95cUxOc1U3SFFCbndmc3JNdVRsN3h5ZE1LX3J0WnZJaDAzbm00VHhaX3oxdUlBSzBEZmlYa2JkOGNRQnhaVTRKdFhNUkVqclY1Q3phMnJ4OUswdDVEU3pzcDdjZ2pFTjkxeFRXZDJPcllmREM1OTRaaDM0UU1KRmoyZGUzMG5RWktnTi1XOURNajZqaTJkbzdR?oc=5) |
| Reuters | Merck licenses SciBrunch cancer drug in deal worth up to $2.13 billion | 2026-09-28 14:00 | [Source Link](https://news.google.com/rss/articles/CBMitgFBVV95cUxQNDdBQWp0eXhySGlJdTloSFcwMVk1WmY1NzVlZldsRDZRTjRRdy0zTHVCbXU5QjRlSWdFWmI2OGNXNmN6SHp2dF9oOEItN1E2dl9kSnZjZVYwT096T1V0aUpvT0pzX29aWVhILVBLMDdZMkRQX2VsZHBrRUJuT3phY1MzQ2Rlcy12OEZWTm9XWG12YmZDVkI1cU1ObWtzNzJOcEN1MklZZ2dQWWxMRGJMQThLZFdFZw?oc=5) |
| Endpoints News | Merck licenses a KRAS G12D inhibitor for $400M upfront | 2026-09-28 14:00 | [Source Link](https://news.google.com/rss/articles/CBMigwFBVV95cUxOb0JoTVRGczZyR2hmUW5yN1E4a0ZNaDE0cnhLRDVZeGU1SmMwYmYyYmI4Mkd1TEQ4Y3pBUWNTSUJqSVBzcFlXbjRjT3U2bUlyVGVMeWpKSnJHODFlOEdFWlBqSlJxM25KcjhkWE1GNThOYjB5cjVxTTdqcUxXbmpDbGgzMA?oc=5) |

---
*Canonical Source: https://www.newsylist.com/trend/2026-09-28/merck-licenses-a-kras-g12d-inhibitor-for-400m-upfront*
*Synthesized by Newsylist Open Intelligence Engine under E-E-A-T journalistic standards.*